Literature DB >> 19451284

Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Kook-Hwan Oh1, Chiweon Kim, Hankyu Lee, Hajeong Lee, Ji Yong Jung, Nam Joong Kim, Kyung-Sang Yu, Kwang-Hee Shin, In-Jin Jang, Curie Ahn.   

Abstract

The pharmacokinetic characteristics of piperacillin sodium were studied in five volunteers undergoing on-line hemodiafiltration (HDF). The subjects were given 2 g of piperacillin sodium intravenously over 1 min and placed on on-line HDF for 4 h starting at 60 min after the piperacillin infusion. Noncompartmental models were employed for estimation of the pharmacokinetic parameters, and intradialytic piperacillin clearance was calculated by the recovery method. The mean volume of distribution and the elimination half-life were 0.27 +/- 0.13 liter/kg (mean +/- standard deviation) and 1.1 +/- 0.6 h, respectively. The total body clearance of piperacillin was 0.19 +/- 0.08 liter/h/kg. Piperacillin clearance through on-line HDF was 0.11 +/- 0.06 liter/h/kg. The mean serum piperacillin concentration was 4.0 +/- 1.9 microg/ml at the end of the 4-h on-line HDF session. The concentration of infused piperacillin recovered in the dialysate was 527 +/- 236 mg (26.3% +/- 11.8%). We suggest the replacement of 500 mg of piperacillin after each on-line HDF session.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451284      PMCID: PMC2715588          DOI: 10.1128/AAC.01670-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.

Authors:  A P MacGowan; R Wise
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

3.  Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

Authors:  E L Francke; G B Appel; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

5.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

6.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

7.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

8.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

Authors:  J A Giron; B R Meyers; S Z Hirschman; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  Piperacillin pharmacokinetics in subjects with chronic renal failure.

Authors:  M I Thompson; M E Russo; J M Matsen; E Atkin-Thor
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  2 in total

1.  Optimization of anti-infective dosing regimens during online haemodiafiltration.

Authors:  Nynke G L Jager; Anthe S Zandvliet; Daniel J Touw; Erik L Penne
Journal:  Clin Kidney J       Date:  2017-03-29

2.  Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections.

Authors:  Yong Kyun Kim; Jin Ah Jung; Hyang Ki Choi; In Gyu Bae; Won Suk Choi; Jian Hur; Sung Joon Jin; Shin Woo Kim; Ki Tae Kwon; Sang Rok Lee; Jae Gook Shin; Sungmin Kiem
Journal:  Infect Chemother       Date:  2016-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.